These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 16788861)

  • 1. A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies.
    Gilbert J; Carducci MA; Baker SD; Dees EC; Donehower R
    Invest New Drugs; 2006 Nov; 24(6):499-508. PubMed ID: 16788861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
    Delaunoit T; Burch PA; Reid JM; Camoriano JK; Kobayash T; Braich TA; Kaur JS; Rubin J; Erlichman C
    Invest New Drugs; 2006 Jul; 24(4):327-33. PubMed ID: 16502355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
    Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
    Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.
    Galmarini CM
    Curr Opin Investig Drugs; 2006 Jun; 7(6):565-73. PubMed ID: 16784028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
    Hidalgo M; Villalona-Calero MA; Eckhardt SG; Drengler RL; Rodriguez G; Hammond LA; Diab SG; Weiss G; Garner AM; Campbell E; Davidson K; Louie A; O'Neil JD; von Borstel R; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 2000 Jan; 18(1):167-77. PubMed ID: 10623707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical trials of tezacitabine [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors.
    Rodriguez GI; Jones RE; Orenberg EK; Stoltz ML; Brooks DJ
    Clin Cancer Res; 2002 Sep; 8(9):2828-34. PubMed ID: 12231523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors.
    Saeki T; Takashima S; Terashima M; Satoh A; Toi M; Osaki A; Toge T; Ohno S; Nomura N; Fukuyama Y; Koizumi W; Taguchi T
    Int J Clin Oncol; 2005 Feb; 10(1):51-7. PubMed ID: 15729602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
    Bendell JC; Rosen LS; Mayer RJ; Goldman JW; Infante JR; Benedetti F; Lin D; Mizuguchi H; Zergebel C; Patel MR
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):925-32. PubMed ID: 26370544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
    de Bono JS; Stephenson J; Baker SD; Hidalgo M; Patnaik A; Hammond LA; Weiss G; Goetz A; Siu L; Simmons C; Jolivet J; Rowinsky EK
    J Clin Oncol; 2002 Jan; 20(1):96-109. PubMed ID: 11773159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.
    Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Ravandi F; Westwood R; Green SR; Chiao JH; Boone PA; Cortes J; Plunkett W
    J Clin Oncol; 2010 Jan; 28(2):285-91. PubMed ID: 19933907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
    J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.
    Overman MJ; Kopetz S; Varadhachary G; Fukushima M; Kuwata K; Mita A; Wolff RA; Hoff P; Xiong H; Abbruzzese JL
    Cancer Invest; 2008 Oct; 26(8):794-9. PubMed ID: 18798063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
    Traina TA; Theodoulou M; Feigin K; Patil S; Tan KL; Edwards C; Dugan U; Norton L; Hudis C
    J Clin Oncol; 2008 Apr; 26(11):1797-802. PubMed ID: 18398145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
    Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
    Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
    Baker SD; Diasio RB; O'Reilly S; Lucas VS; Khor SP; Sartorius SE; Donehower RC; Grochow LB; Spector T; Hohneker JA; Rowinsky EK
    J Clin Oncol; 2000 Feb; 18(4):915-26. PubMed ID: 10673535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sapacitabine for cancer.
    Liu X; Kantarjian H; Plunkett W
    Expert Opin Investig Drugs; 2012 Apr; 21(4):541-55. PubMed ID: 22329458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
    Fabi A; Metro G; Papaldo P; Mottolese M; Melucci E; Carlini P; Sperduti I; Russillo M; Gelibter A; Ferretti G; Tomao S; Milella M; Cognetti F
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):717-25. PubMed ID: 18071704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nelarabine: a novel purine antimetabolite antineoplastic agent.
    Buie LW; Epstein SS; Lindley CM
    Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.